Prices as of 2026/10/30 close
Company comparison · Cosmetics
POLA ORBIS is the bigger company, with revenue of ¥170.3B — 2.6x Noevir's ¥64.7B.
Noevir earns more on each yen of sales, with an operating margin of 17.1% — 7.9 points above POLA ORBIS (9.2%).
Revenue growth in the latest results: Noevir +1.4%, POLA ORBIS +0.0%. For next year, POLA ORBIS guides for the fastest operating profit growth (+10.2%).
Over the past year the shares moved POLA ORBIS +8.9%, Noevir +5.3%.
Head-to-head wins14 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
POLA ORBIS aheadPOLA ORBIS 3 : Noevir 0
Revenue: POLA ORBIS ¥170.3B / Noevir ¥64.7B
ProfitabilityInvestors
Noevir aheadPOLA ORBIS 0 : Noevir 3
Operating margin: POLA ORBIS 9.2% / Noevir 17.1%
GrowthInvestors
POLA ORBIS aheadPOLA ORBIS 3 : Noevir 1
Revenue growth (YoY): POLA ORBIS +0.0% / Noevir +1.4%
Stock & balance sheetInvestors
POLA ORBIS aheadPOLA ORBIS 3 : Noevir 0
Share price, 1 year: POLA ORBIS +8.9% / Noevir +5.3%
Pay & workforceJob seekers
Noevir aheadPOLA ORBIS 0 : Noevir 1
Average tenure: POLA ORBIS 4.9 yrs / Noevir 8.8 yrs
| Metric | POLA ORBIS | Noevir | Gap |
|---|---|---|---|
| Revenue | ◎¥170.3B | ¥64.7B | 2.6x |
| Operating profit | ◎¥15.7B | ¥11.1B | 1.4x |
| Net income | ◎¥9.5B | ¥8.0B | 1.2x |
| Metric | POLA ORBIS | Noevir | Gap |
|---|---|---|---|
| Operating margin | 9.2% | ◎17.1% | 7.9pt |
| Net margin | 5.6% | ◎12.4% | 6.8pt |
| ROE | 5.8% | ◎15.0% | 9.2pt |
| Revenue per employee | ¥613M | — |
| Metric | POLA ORBIS | Noevir | Gap |
|---|---|---|---|
| Revenue growth (YoY) | +0.0% | ◎+1.4% | 1.4pt |
| Operating profit growth (YoY) | ◎+13.6% | −3.0% | 16.6pt |
| Guidance: revenue growthnext FY plan | ◎+1.6% | +0.4% | 1.2pt |
| Guidance: op. profit growthnext FY plan | ◎+10.2% | +2.9% | 7.3pt |
| Metric | POLA ORBIS | Noevir | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+8.9% | +5.3% | 3.6pt |
| Share price, 3 months | ◎+1.5% | −9.4% | 10.9pt |
| P/E (trailing)lower = cheaper | 33.2x | 19.4x | |
| Equity ratio | ◎82.4% | 70.9% | 11.5pt |
| Share price (close) | ¥1,420 | ¥4,565 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | POLA ORBIS | Noevir | Gap |
|---|---|---|---|
| Average salary | ¥7.66M | — | |
| Starting salary (monthly) | ¥296,000 | — | |
| Average tenure | 4.9 yrs | ◎8.8 yrs | 3.9 |
| Average age | 43.1 | 43.9 | 0.8 |
| Employees | 278 | 49 | 5.7x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥1,420+8.9% (1Y)
POLA ORBIS +8.9% over 1Y. Compared: Noevir +5.3%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
POLA ORBIS3 segments
Noevir3 segments
ARevenue in the latest results: POLA ORBIS ¥170.3B, Noevir ¥64.7B. POLA ORBIS is the bigger company, with revenue of ¥170.3B — 2.6x Noevir's ¥64.7B.
AOperating margins: Noevir 17.1%, POLA ORBIS 9.2%. Noevir turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): POLA ORBIS +8.9%, Noevir +5.3%. POLA ORBIS has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
